SARCOMA

With an overall response rate of 38.6% and a consistent safety profile of that seen in prior trials, afamitresgene autoleucel continues to show clinical responses in patients with late-stage synovial sarcoma.

Matthew Ingham, MD, discusses understanding the genomics of sarcomas and how molecular testing can be useful in this space.

Fifty percent of patients with advanced soft tissue sarcoma enrolled in the phase 1b study of camsirubicin and pegfilgrastim had stable disease.

Matthew Ingham, MD, discusses the unique biology of uterine sarcomas.

A suspected unexpected serious adverse reaction to seclidemstat led the developer to pause a phase 1/2 evaluating the agent in patients with Ewing and FET-rearranged sarcoma.

Twelve-week safety data from the phase 2 ENVASARC trial of envafolimab alone and in combination with ipilimumab in patients with undifferentiated pleomorphic sarcoma and myxofibrosarcoma support proceeding with enrollment of patients in the trial.

The FDA has granted an orphan drug designation to DUNP19 for patients with osteosarcoma.

The FDA granted an orphan drug designation to AVA6000 for the treatment of patients with soft tissue sarcoma.

Results from a phase 2 study revealed nivolumab plus ipilimumab to demonstrate promising clinical activity and manageable safety signals in previously treated patients with classical Kaposi sarcoma who had disease progression.

For sarcoma awareness month, Lisa Ercolano, MD, discusses the need for a multidisciplinary approach to treating patients with osteosarcoma.

The FDA has approved crizotinib as treatment for adult and pediatric patients aged 1 year and older with unresectable, recurrent, or refractory inflammatory ALK-positive myofibroblastic tumors.

IfIosfamide treatment improved event-free survival compared with topotecan plus cyclophosphamide in patients with relapsed/refractory Ewing sarcoma, phase 2/3 study results show.

With expanding knowledge of the molecular characteristics of uterine sarcomas, investigators are working to develop treatments specific to each subtype.

Results of the SEAL study revealed a 30% progression-free survival improvement in patients with advanced, metastatic dedifferentiated liposarcoma who underwent selinexor therapy as well as other efficacy and safety benefits.

Pembrolizumab may be a new therapeutic option for patients classic and endemic Kaposi’s sarcoma, according to phase 2 study results.

Orphan drug designation has been granted to Veyonda as a form of treatment in patients with soft tissue sarcoma.

Patients with sarcoma may respond to treatment with immune checkpoint inhibitors, but identifying patients who are most likely to respond to this therapy is an ongoing obstacle and suggests the need for further research.

There remains a need for biomarkers of primary gastrointestinal stromal tumor subclones to characterize invasion or metastasis, according to Jonathan A. Fletcher, MD.

In season 3, episode 2 of Targeted Talks, Mark Agulnik, MD, discusses molecular testing for patients with sarcoma, treatment with targeted therapies, and ongoing research.

For patients with advanced synovial sarcoma or myxoid/ round cell liposarcoma, afamitresgene autoleucel is a promising novel therapy.

Results presented during the 2022 January ASCO Plenary Series showed that ripretinib did perform better than sunitinib in terms of the objective response rate, and the safety profile of the drug was favorable compared with sunitinib.

Devimistat shows therapeutic potential in patients with clear cell sarcoma after dose-escalation ends with no observed dose-limiting toxicities.

IMX-110 may soon be granted fast track designation for the treatment of rhabdomyosarcoma children.

In season 2, episode 10 of Targeted Talks, Sandra P. D'Angelo, MD, and Katherine Poruk, MD, discuss frontline treatment practices in the sarcoma space.

FDA approval has been granted to nab-sirolimus for intravenous use as treatment of patients with advanced malignant perivascular epithelioid cell tumors.